The Economics of Prescription Drug Importation
June 9, 2004
Dawn M. Gencarelli
This meeting explored the potential economic impact of prescription drug importation, including its potential effect on drug prices, supply, spending, and research and development. Building upon a recent Congressional Budget Office (CBO) report, “Would Prescription Drug Importation Reduce U.S. Spending?” the meeting examined recent developments in the ongoing debate over drug importation, including passage of the Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003.
Colin S. Baker, Associate Analyst, Health and Human Resources Division, Congressional Budget Office; Margaret Nowak, Analyst, Health Cost Estimate Unit, Congressional Budget Office; Randall Lutter, PhD, Chief Economist, Food and Drug Administration; Stephen W. Schondelmeyer, PhD, Professor of Pharmaceutical Economics, University of Minnesota College of Pharmacy
See the CBO report, “Would Prescription Drug Importation Reduce U.S. Spending?” (April 29, 2004).